Inventiva

About Inventiva

Inventiva Pharma is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders, and oncology. They aim to address diseases such as non-alcoholic steatohepatitis (NASH) and mucopolysaccharidosis (MPS) through innovative drug candidates and a robust pipeline supported by a proprietary discovery engine.

Products & Services

Lanifibranor:A drug candidate in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH), targeting liver fat accumulation, inflammation, liver cell injury, and fibrosis. It has shown significant efficacy in Phase IIb studies and received Breakthrough Therapy Designation by the FDA.

Odiparcil:An orally-available small molecule in development for mucopolysaccharidosis (MPS), designed to modify glycosaminoglycan (GAG) synthesis. It demonstrated efficacy and a favorable safety profile in a Phase IIa study for adult MPS VI patients.

YAP-TEAD:A program in the pipeline targeting oncology, though specific details on development stage or focus are not provided in the content.

Oral investigational therapy for MASH

Specialties

Fibrosis Lysosomal Storage Disorders Oncology Non-Alcoholic Steatohepatitis (NASH) Mucopolysaccharidosis (MPS) Nuclear Receptors Transcription Factors Epigenetic Modulation MASH (metabolic dysfunction-associated steatohepatitis) Metabolic dysfunction Inflammation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 140400000 MR: - FA: €130m FAN: 140400000	D: 2026-06-16 FD: 2026-06-16	2 investors
2	RT: Debt T: - FT: Debt	A: 81000000 MR: - FA: 75 million FAN: 81000000	D: 2026-06-12 FD: 2026-06-12	2 investors
3	RT: Debt and Equity T: - FT: Debt and Equity	A: 120000000 MR: - FA: $120 million equity + up to €130 million debt FAN: 120000000	D: 2026-06-02 FD: 2026-06-02	4 investors
4	RT: Public Offering T: - FT: Public Offering	A: 172500000 MR: - FA: approximately $172.5 million FAN: 172500000	D: 2025-11-17 FD: 2025-11-17	2 investors
5	RT: Public Offering T: - FT: Public Offering	A: 150000000 MR: - FA: approximately $150M FAN: 150000000	D: 2025-11-13 FD: 2025-11-13	3 investors
6	RT: ATM Program T: - FT: ATM Program	A: 100000000 MR: - FA: up to $100 million FAN: 100000000	D: 2025-10-14 FD: 2025-10-14	1 investors
7	RT: Milestone Payment T: - FT: Milestone Payment	A: 10000000 MR: - FA: $10 million FAN: 10000000	D: 2025-07-07 FD: 2025-07-07	1 investors
8	RT: Structured Financing T: - FT: Structured Financing	A: 115600000 MR: - FA: €115.6 million FAN: 115600000	D: 2025-05-05 FD: 2025-05-05	11 investors
9	RT: Equity Financing T: - FT: Equity Financing	A: 23112000 MR: - FA: €21.4 million FAN: 23112000	D: 2024-12-16 FD: 2024-12-16	7 investors
10	RT: Equity financing T: - FT: Equity financing	A: 30000000 MR: - FA: up to €348 million and up to $30 million in milestone payments FAN: 30000000	D: 2024-10-14 FD: 2024-10-14	11 investors
11	RT: Debt T: - FT: Debt	A: 25000000 MR: - FA: €25 million FAN: 25000000	D: 2024-01-10 FD: 2024-01-10	1 investors
12	RT: Equity Financing T: - FT: Equity Financing	A: 38174000 MR: - FA: approximately €35.7 million FAN: 38174000	D: 2023-08-31 FD: 2023-08-31	3 investors
13	RT: Equity Financing (Capital Increase and Royalty Certificates) T: - FT: Equity Financing (Capital Increase and Royalty Certificates)	A: 38556000 MR: - FA: approximately €35.7 million FAN: 38556000	D: 2023-08-31 FD: 2023-08-31	3 investors

Debt Latest

2026-06-16

$140.4M

2 investors (Pro only)

Debt 2026-06-12

$81.0M

Debt and Equity 2026-06-02

$120.0M

View 12 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Andrew Obenshain

Chief Executive Officer

N

Nazira Amra

Chief Commercial Strategy Officer

J

Jason Campagna

President of R&D and Chief Medical Officer

P

Pascaline Clerc

Executive Vice President, External and Corporate Affairs

S

Susan Coles

Chief Legal Officer

P

Pamela Herbster

Chief People Officer

View 25 more team members with Pro

Unlock Full Team Directory

Recent News

Inventiva Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised